Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer

• Published in: International journal of medical sciences 2011-03, Vol.8 (3), p.210-215
• Main Authors: Seki, Kyoko, Senzaki, Kenzou, Tsuduki, Yasuo, Ioroi, Takeshi, Fujii, Michiko, Yamauchi, Hiroko, Shiraishi, Yukinari, Nakata, Izumi, Nishiguchi, Kohshi, Matsubayashi, Teruhisa, Takakubo, Yoshihide, Okamura, Noboru, Yamamori, Motohiro, Tamura, Takao, Sakaeda, Toshiyuki
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Colorectal Neoplasms - complications; Colorectal Neoplasms - drug therapy; Drug Hypersensitivity - diagnosis; Drug Hypersensitivity - epidemiology; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Fluorouracil - therapeutic use; Humans; Hypersensitivity - complications; Japan - epidemiology; L-Lactate Dehydrogenase - blood; Leucovorin - administration & dosage; Leucovorin - adverse effects; Leucovorin - therapeutic use; Leukocyte Count; Male; Middle Aged; Monocytes - cytology; Neutrophils - cytology; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - adverse effects; Organoplatinum Compounds - therapeutic use; Oxaliplatin; Research Paper; Risk Factors; Sex Characteristics
• ISSN: 1449-1907; 1449-1907
• DOI: 10.7150/ijms.8.210

Previously, we suggested that oxaliplatin (L-OHP)-related grade 3/4 hypersensitivity reactions occurred immediately after the initiation, but grade 1/2 reactions did not. This study was conducted to clarify the risk factors for L-OHP-related hypersensitivity reactions. Clinical data from 108 Japanese patients with colorectal cancer were analyzed, who were treated with L-OHP-containing regimens, FOLFOX4 and/or mFOLFOX6. The risk factors examined included demographic data, preexisting allergies, laboratory test data, treatment regimen, treatment line of therapy, pretreatment with steroids, total number of cycles and cumulative amount of L-OHP. The incidence of grade 1/2 and grade 3/4 hypersensitivity reactions were found at 13.0% (14/108) and 9.3% (10/108), respectively. Female (P = 0.037), preexisting allergies (P = 0.004) and lower level of lactate dehydrogenase (P = 0.003) were risk factors for grade 1/2 hypersensitivity reactions, and higher neutrophil count (P = 0.043) and lower monocyte count (P = 0.007) were for grade 3/4 reactions. Total number of cycles were larger in the patients with grade 3/4 reactions than those without reactions (P = 0.049). Further extensive examination with a large number of patients is needed to establish a patient management strategy.